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Summary
Background Asthma is the most common chronic disease in children globally. The Global Asthma Network (GAN) 
Phase I study aimed to determine if the worldwide burden of asthma symptoms is changing.
Methods This updated cross-sectional study used the same methods as the International Study of Asthma and 
Allergies in Childhood (ISAAC) Phase III. Asthma symptoms were assessed from centres that completed GAN 
Phase I and ISAAC Phase I (1993–95), ISAAC Phase III (2001–03), or both. We included individuals from two age 
groups (children aged 6–7 years and adolescents aged 13–14 years) who self-completed written questionnaires at 
school. We estimated the 10-year rate of change in prevalence of current wheeze, severe asthma symptoms, ever 
having asthma, exercise wheeze, and night cough (defined by core questions in the questionnaire) for each centre, 
and we estimated trends across world regions and income levels using mixed-effects linear regression models with 
region and country income level as confounders.
Findings Overall, 119 795 participants from 27 centres in 14 countries were included: 74 361 adolescents (response 
rate 90%) and 45 434 children (response rate 79%). About one in ten individuals of both age groups had wheeze in the 
preceding year, of whom almost half had severe symptoms. Most centres showed a change in prevalence of 2 SE or 
more between ISAAC Phase III to GAN Phase I. Over the 27-year period (1993–2020), adolescents showed a significant 
decrease in percentage point prevalence per decade in severe asthma symptoms (–0·37, 95% CI –0·69 to –0·04) and 
an increase in ever having asthma (1·25, 0·67 to 1·83) and night cough (4·25, 3·06 to 5·44), which was also found in 
children (3·21, 1·80 to 4·62). The prevalence of current wheeze decreased in low-income countries (–1·37, 
–2·47 to –0·27), in children and –1·67, –2·70 to –0·64, in adolescents) and increased in lower-middle-income 
countries (1·99, 0·33 to 3·66, in children and 1·69, 0·13 to 3·25, in adolescents), but it was stable in upper-middle-
income and high-income countries.
Interpretation Trends in prevalence and severity of asthma symptoms over the past three decades varied by age group, 
country income, region, and centre. The high worldwide burden of severe asthma symptoms would be mitigated by 
enabling access to effective therapies for asthma.
Funding International Union Against Tuberculosis and Lung Disease, Boehringer Ingelheim New Zealand, 
AstraZeneca Educational Grant, National Institute for Health Research, UK Medical Research Council, European 
Research Council, and Instituto de Salud Carlos III.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
Asthma is the most common non-communicable disease 
in children and one of the most common chronic 
diseases in adulthood.1,2 It is a major global health 
problem, with estimated 495 100 deaths from asthma 
in 2017,3 and 22·8 million disability-adjusted life-years 
in 2017.4 More than 1000 asthma deaths each day are 
similar to the number of deaths from malaria.5 Cross-
sectional comparisons of the prevalence of asthma in 
populations require standardised methods that can be 
implemented in a wide range of settings, and the 
International Study of Asthma and Allergies in 
Childhood (ISAAC) is the only worldwide study to 
achieve this.6 ISAAC Phase I (1993–95), repeated in 
Phase III (2001–03), identified that the prevalence of 
asthma symptoms (current wheeze) in school-aged 
children (aged 6–7 years and 13–14 years) was rising in 
some low-income and middle-income countries.7,8
The Global Asthma Network (GAN) was established 
in 2012, building on the success of ISAAC and 
incorporating a new collaboration with the International 
Union Against Tuberculosis and Lung Disease. One of 
GAN’s core activities, GAN Phase I (building on ISAAC 
and using an identical approach and methods)9 includes 
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global surveillance of prevalence and severity of asthma 
symptoms,10 making it the only source of new population-
based data on worldwide trends in prevalence of asthma 
symptoms directly comparable to data from ISAAC 
Phases I and III. Public health interventions need to be 
based on science, with up-to-date evidence of the size 
and trends of health issues.
We hypothesised that globally, the burden (prevalence 
and severity) of asthma symptoms is changing in school-
aged children worldwide. The aim was to conduct asthma 
symptom surveillance around the world in two age groups 
of school pupils to examine time trends in prevalence and 
severity of asthma symptoms from centres that completed 
GAN Phase I and ISAAC Phase I, Phase III, or both.10
Methods 
Study design and participants 
ISAAC Phase I and Phase III were multicentre, multi-
country, cross-sectional, population studies in school-
aged children, following standardised methods that have 
been well described11,12 and are highly replicable.13 This 
enabled comparisons of prevalence and severity of 
asthma symptoms between ISAAC Phase I and Phase III 
and GAN Phase I. Centres that completed GAN Phase I 
and ISAAC Phase I, Phase III, or both were the study 
centres for this analysis, and key personnel at the GAN 
Global Centre (Auckland, New Zealand) were the same 
throughout ISAAC Phase I, ISAAC Phase III, and GAN 
Phase I.
Each GAN Phase I investigator completed a 
registration document and followed the GAN manual.14 
They gained approval from their local ethics committee 
and replicated the methods that had been used in their 
centres for ISAAC; this was documented in the centre 
report,14 which enabled checks to ensure the use of the 
same geographical sampling frame, sample size, age 
groups, method of selecting pupils, time of year for 
data collection, and translations as had been used in 
ISAAC.15 From the sampling frame, ten or more schools 
were selected at random (or all schools if fewer than 
ten). The GAN Global Centre checked each centre 
report with the investigator for validity.
As in ISAAC, the compulsory age group was individuals 
aged 13–14 years (adolescents) who self-completed 
written questionnaires at school. The inclusion of 
individuals aged 6–7 years (children) was optional, and 
their questionnaires were completed at home by their 
parents or caregivers. All students of the specified age 
within schools were included and selected by grade, 
level, or year or by chronological age. Local ethics 
committees determined the method of consent (either 
passive or written) from parents or caregivers of both age 
groups; however, GAN recommended passive consent as 
written consent could reduce response rate,16 and the 
adolescents agreed by participating. Additionally, GAN 
Phase I included questionnaires completed by the 
parents about themselves, not reported here.
Procedures 
We used seven core written asthma questions for 
comparisons in this Article. Current wheeze was defined 
as a positive answer to the question “have you (has this 
child) had wheezing or whistling in the chest in the past 
12 months?” Severe asthma symptoms were defined as 
participants with current wheeze who, in the preceding 
12 months, had four or more attacks of wheeze, one or 
more nights per week with sleep disturbance from 
wheeze, or wheeze affecting their speech.17 Ever having 
asthma (asthma ever) was defined as a positive answer to 
the question ‘‘have you (has this child) ever had asthma?’’ 
Exercise wheeze was defined by a positive answer to the 
question “in the past 12 months, has your (has this 
child’s) chest sounded wheezy during or after exercise?” 
And lastly, night cough was defined as a positive answer 
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Research in context
Evidence before this study
We searched PubMed, Web of Science, and Scopus on 
March 2, 2020, for papers in English published from Jan 1, 
1990, to Dec 31, 2019. The search terms used were “asthma or 
asthma prevalence”, “children or adolescent”, “cross-sectional”, 
“time trend or repeated”, “global or worldwide or international”, 
with the search narrowed subsequently with the search terms 
“review or meta-analysis” added. A recent review of worldwide 
trends in asthma prevalence found that the International Study 
of Asthma and Allergies in Childhood (ISAAC) was the only 
global study providing direct evidence on changes in prevalence 
of asthma in school-aged children.
Added value of this study
To our knowledge, the Global Asthma Network Phase I study, 
adopting the same methods as ISAAC, produced the first 
comparable estimates of prevalence and severity of asthma 
symptoms in school-aged children over nearly three decades 
(1993–2020), from 27 centres in 14 countries in the Africa and 
Eastern Mediterranean, America, Europe, and South-East Asia 
and Western Pacific regions.
Implications of all the available evidence
Asthma is a major worldwide public health problem in 
school-aged children. Implementing strategies to reduce the 
prevalence and severity of asthma symptoms (and the 
associated avoidable asthma morbidity and mortality and 
subsequent burden of related diseases, including chronic 
obstructive pulmonary disease) should be a priority for the 
21st century.
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to the question “in the past 12 months have you (has this 
child) had a dry cough at night, apart from associated 
with a cold or chest infection?”
Data and the centre report from each participating 
centre were submitted to the GAN Global Centre, and 
quality control checks were completed. Centres with 
13–14-years age group 6–7-years age group












Africa and Eastern Mediterranean
Nigeria (Ibadan) A Falade 85·0% May, 2018 16·7 ·· ·· ·· ··
South Africa (Cape Town) H J Zar 84·4% August, 2017 15·2 ·· ·· ·· ··
Sudan (Khartoum) M Nour 99·9% March, 2017 14·1 ·· ·· ·· ··
Syria (Lattakia) G Dib 99·6% April, 2019 17·3 Y Mohammad 93·0% May, 2019 16·2
Region total ·· ·· December, 2017 15·7 ·· ·· May, 2019 16·2
Americas
Chile (South Santiago) J Mallol 81·9% March, 2015 13·3 ·· ·· ·· ··
Costa Rica (Costa Rica) M Soto-Martinez 67·5% February, 2018 16·1 M Soto-Martinez 64·5% January, 2018 16·0
Ecuador (Quito) A Cabrera Aguilar 100·0% April, 2019 15·9 ·· ·· ·· ··
Mexico (Ciudad Victoria) R García-Almaráz 82·3% December, 2015 12·7 R García-Almaráz 81·5% February, 2016 12·9
Mexico (Mexicali) J V Mérida-Palacio 83·7% April, 2016 13·7 J V Mérida-Palacio 77·0% March, 2016 13·3
Mexico (Mexico City [North 
Area])
B E Del Río Navarro 93·8% September, 2015 12·9 B E Del Río Navarro 86·7% June, 2016 13·6
Mexico (Monterrey) S N González-Díaz 88·0% December, 2017 16·7 ·· ·· ·· ··
Mexico (Toluca Urban Area) E M Navarrete-
Rodriguez
98·1% October, 2015 13·1 E M Navarrete-
Rodriguez
95·7% April, 2016 13·5
Nicaragua (Managua) J F Sánchez 90·5% November, 2018 16·5 J F Sánchez 87·9% November, 
2018
16·4
Region total ·· ·· December, 2016 14·5 ·· ·· January, 2017 14·4
Europe
Spain (A Coruña) A López-Silvarrey 
Varela
92·1% January, 2019 15·2 A López-Silvarrey 
Varela
71·0% January, 2019 15·3
Spain (Bilbao) C González Díaz 91·1% September, 2018 16·8 C González Díaz 55·2% August, 2018 16·7
Spain (Cartagena) L García-Marcos 73·8% January, 2016 13·9 L García-Marcos 65·9% January, 2016 14·0
Region total ·· ·· December, 2017 15·4 ·· ·· November, 
2017
15·3
South-East Asia and Western Pacific
India (Bikaner) M Sabir 90·1% November, 2017 16·3 ·· ·· ·· ··
India (Chandigarh) M Singh 100·0% October, 2017 15·9 ·· ·· ·· ··
India (Jaipur) V Singh 98·7% November, 2017 16·3 V Singh 75·8% November, 
2017
16·3
India (Kottayam) T U Sukumaran 85·3% October, 2017 15·3 T U Sukumaran 68·4% December, 2017 15·5
India (Lucknow) S Awasthi 94·0% October, 2017 16·0 S Awasthi 91·3% October, 2017 15·9
India (New Delhi) S K Kabra 100·0% November, 2017 16·0 S K Kabra 80·9% January, 2018 16·1
India (Pune) S Salvi 99·6% October, 2017 15·9 S Salvi 79·8% October, 2017 15·9
New Zealand (Auckland) M I Asher 85·5% October, 2018 16·7 M I Asher 63·7% July, 2018 16·4
Taiwan (Taipei) J-L Huang 93·0% October, 2017 15·8 J-L Huang 76·3% October, 2017 15·8
Thailand (Bangkok) S Chinratanapisit 97·9% September, 2017 16·1 S Chinratanapisit 86·3% August, 2017 16·1
Region total ·· ·· November, 2017 16·0 ·· ·· November, 
2017
16·0
World total ·· ·· August, 2017 15·4 ·· ·· August, 2017 15·3
The Athens centre is not presented because its ISAAC data are from Phase I alone; the Chandigarh centre is not presented in the 6–7-years age group because its ISAAC data are from Phase I alone. For the 13–14-years 
age group, methodology notes for centres with GAN Phase I data alone are the following: no date of birth on the questionnaire (Ibadan, Taipei); response rate lower than 80% (Costa Rica, Cartagena); age and birth 
date showed high inconsistencies (Quito); fewer than ten schools used when ten or more schools were available (Ciudad Victoria, Mexico City [north area], Toluca Urban Area, Auckland, Bangkok); only age was 
reported reliably (Monterrey); single data entry (Monterrey); no age on the questionnaire (Chandigarh, New Delhi); questionnaires completed at home by parents (Kottayam); and more than 20% of questionnaires 
missing age and date of birth (Bangkok). For the 6–7-years age group, methodology notes for centres with GAN Phase I data alone are the following: response rate lower than 70% (Costa Rica, Bilbao, Cartagena, 
Kottayam, Auckland); no date of birth on the questionnaire (Taipei); no age on the questionnaire (New Delhi); fewer than ten schools used when ten or more schools were available (Bangkok); and more than 20% of 
questionnaires missing age and date of birth (Bangkok). GAN=Global Asthma Network. ISAAC=International Study of Asthma and Allergies in Childhood. *GAN Phase I. †ISAAC Phase III to GAN Phase I.
Table 1: Data collection details in each study centre
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minor deviations from the methods were included in 
analyses, and these deviations are specified in footnotes 
in the tables, as in ISAAC.18 The data were then 
transferred to one of two designated GAN Phase I data 
centres for checking and analysis: Murcia (Spain) for 
Spanish-speaking and Portuguese-speaking centres and 
London (UK) for all other languages. A uniform approach 
to data processing, checking, and analysis was developed, 
using Stata versions 13–15.19
The mean date of questionnaire completion in each 
centre was used, rather than the year alone as had 
occurred in ISAAC time-trend studies.7,8 High levels of 
participation were required for inclusion because 
absent school pupils might be away from school due to 
asthma symptoms: response rate was required to be at 
least 80% for adolescents and 70% for children.9,11,18 The 
response rate was defined as the number of core 
asthma symptom questionnaires returned with at least 
some symptom data, divided by the number of pupils 
in the age group. Three of the centre datasets received 
(one for adolescents and two for children) were 
excluded from the analyses due to poor (<50%) 
response rates.
In each centre, estimates of prevalence of symptoms 
for each age group were obtained by dividing the number 
of positive responses to each question by the number of 
completed questionnaires. If apparent inconsistencies 
were found between responses to a main question and a 
branched question (one dependent on the response to a 
main question), these were accepted and not recoded. 
For regional and global summaries, data for each centre 
were weighted by the sample size.
We obtained country income categories from the World 
Bank, with countries categorised into low-income, lower-
middle-income, upper-middle-income, and high-income 
countries.20 The gross national income 2001 classification 
was used, because it was close to the timing of ISAAC 
Phase III, from which most data were available. 
Countries were allocated to four regions corresponding 
to WHO regions of the world, with South-East Asia and 
Western Pacific regions combined and Africa and Eastern 
Mediterranean regions combined, because of the small 
number of centres in these regions. WHO regions and 
country income category are not synonymous.
Outcomes and statistical analysis 
We sought a sample size of 3000 participants for each 
age group (with a minimum of 1000 deemed acceptable), 
a stringent requirement because of the number of 
hypotheses being tested. 
We examined changes in prevalence over time from 
ISAAC Phase I to GAN Phase I. We calculated the 10-year 
change in prevalence of symptoms for each centre using 
the difference between the two timepoints (eg, GAN 
Phase I and ISAAC Phase III) divided by the number of 
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We derived estimates of the absolute 10-year rate of 
change in current wheeze, severe asthma symptoms, 
ever having asthma, exercise wheeze, and night cough 
for each centre. We calculated the SE of this change to 
account for school-level clustering.19 We used Bland-
Altman plots to examine the relationship between 
change in prevalence and average prevalence between 
timepoints, to remove the influence of sampling error 
(regression to the mean)21 when comparing the trends in 
higher or lower prevalence areas. The relationship was 
assessed with Spearman’s rank correlation.
To examine trends over time in different types of 
countries or centres, multilevel modelling was 
undertaken. Along with GAN Phase I centres who 
participated in ISAAC, we included ISAAC-only 
centres with data from both ISAAC Phases I and III7 
(94 centres with adolescents and 57 centres with 
children). This enabled us to estimate trends in 
prevalence across the full 27-year period (1993–2020) 
using all available time trends of centres in one mixed-
effects linear regression model. Some centres had 
complete three-point time trend data available for the 
periods of ISAAC Phase I to ISAAC Phase III to GAN 
Phase I, whereas others had only ISAAC Phase III to 
GAN Phase I, ISAAC Phase I to GAN Phase I, or 
ISAAC Phase I to ISAAC Phase III.
We included country-level and centre-level random 
intercepts in the mixed-effects linear regression models. 
The estimated time trend could therefore be interpreted 
as the within-centre absolute change in percentage point 
prevalence per decade. Data from both age groups were 
included in the one model to improve model efficiency. 
We included age group as an a-priori confounder and 
effect modifier to assess time trends in each age group 
separately.
We considered country income category and region as 
confounders and effect modifiers of the time trend. 
Therefore, our analyses controlled, by stratification, for 
age group, region of the world, and country income level. 
In all centres, boys and girls were approximately evenly 
distributed, so we did not control for sex. We also tested 
for evidence against a linear form for the time trend 
through the introduction of a quadratic term. The main 
models were additionally fitted to estimate the time trend 
in severe wheeze, exercise wheeze, night cough, and ever 
having asthma.
To consider the effect of the level of prevalence of 
current wheeze on the change in prevalence of current 
wheeze, we additionally fitted separate models that 
included level of prevalence in ISAAC Phase III (or 
midpoint if no ISAAC Phase III data were available).
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report; and no role in the decision to 
submit the paper for publication.
Results
Data were available for 27 centres, in 14 countries in all 
four regions (Africa and Eastern Mediterranean, 
America, Europe, and South-East Asia and Western 
Pacific) that had completed ISAAC Phase I, Phase III, or 
both and for which GAN Phase I methods and data 
checks were completed by Jan 29, 2021. Overall, 
119 795 participants from GAN Phase I were included: 
74 361 adolescents in 27 centres (response rate 90%, 
range 68–100) and 45 434 children in 19 centres (response 
rate 79%, range 55–100; table 1; appendixes 2, 3). For the 
27 centres in GAN Phase I with data available for 
adolescents, 13 had data from ISAAC Phase III alone, 
13 had data from both ISAAC Phases I and III, and one 
(Athens) had data for ISAAC Phase I alone. For the 
19 centres in GAN Phase I with data available for 
children, nine had data from ISAAC Phase III alone, 
nine had data from both ISAAC Phases I and III, and 
one (Chandigarh) had data from ISAAC Phase I alone.
GAN Phase I was undertaken between March 2, 2015 
and Feb 28, 2020, with the date of data collection varying 
by centre. There was an average of 15·4 years 
(range 12·7–17·3) between ISAAC Phase III and GAN 
Phase I and 22·7 years (19·5–25·5) between ISAAC 
Phase I and GAN Phase I; dates of data collection were 
similar between the adolescent group and children 
group.
For current wheeze, in GAN Phase I, the prevalence in 
adolescents ranged from 0·9% (New Delhi, India) 
to 21·3% (Cape Town, South Africa), with a mean of 10·4% 
(95% CI 7·8–12·8); and the prevalence in children ranged 
from 1·1% (Lucknow, India) to 23·2% (Costa Rica), with a 
mean of 9·9% (7·3–12·4; tables 2, 3). The Bland Altman 
plots showed that the underlying prevalence of current 
wheeze was not associated with the magnitude of change 
(appendix 1, p 6).
We assessed the changes within centres in absolute 
prevalence of current wheeze from ISAAC (Phases I 
and III) to GAN Phase I (figure). Within each age group, 
most centres in both age groups showed significant 
(≥2 SE up or down) changes in current wheeze and 
severe asthma symptoms. For prevalence of current 
wheeze in adolescents, ten centres showed an SE 
decrease of 2 or more, seven showed an SE increase of 2 
or more, and nine showed an SE change lower than 2 
(appendix 1, p 8). For prevalence of current wheeze in 
children, nine centres showed an SE decrease of 2 or 
more, five showed an SE increase of 2 or more, and four 
showed an SE change lower than 2 (appendix 1, p 12). 
Within centres and in both age groups, the pattern of 
changes in prevalence of severe asthma symptoms 
(appendix 1, pp 9, 13) and ever having asthma 
(appendix 1, pp 10, 14) was similar to the changes in 
current wheeze. Additionally, the pattern of changes in 
prevalence of exercise wheeze and night cough was 
similar to those in current wheeze in both age groups 
(tables 2, 3).
See Online for appendix 2 and 3
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The regression models examined whether within-
centre changes were, collectively, compatible with chance 
or real trends. The models showed the effects of age 
group, region, and country income group upon time 
trends in current wheeze to be minimally altered by 
adjustment for their mutual confounding (data not 
shown). Although we observed no evidence for age group 
as an effect modifier (p=0·67), we decided a priori to 
stratify on this variable due to the importance of showing 
age group-specific results. We observed evidence of an 
additional effect modification with both income group 
(p=0·002) and region (p=0·0002), but the low number of 
centres in each stratum meant that we did not consider 
these effect modifiers together.
After stratifying by age group, adolescents showed a 
decrease in percentage point prevalence per decade of 
severe asthma symptoms and an increase in ever having 
asthma and night cough, which was also found in 
children (table 4). Stratification by country income group 
(adjusted for region) showed a decrease in prevalence of 
current wheeze among low-income countries in both age 
groups. However, we found an increase in prevalence of 
current wheeze among both age groups in lower-middle-
income countries, but no change in upper-middle-
income and high-income countries (table 4). Stratification 
by world region (adjusted for income group) showed an 
increase in prevalence of current wheeze in the Africa 
and Eastern Mediterranean region for both age groups, 
whereas the South-East Asia and Western Pacific regions 
showed decreased prevalence of current wheeze (table 4). 
We observed no evidence of a change in prevalence for 
the regions of America and Europe in either age group. 
We assessed nine strata across two age groups and five 
symptom outcomes, but not all of these are statistically 
independent. Within-centre trends in prevalence of 
related symptoms, and of a given symptom across age 
groups, might be correlated.
The results of the models for the other four outcome 
variables showed that the pattern for prevalence of severe 
asthma symptoms and exercise wheeze was similar to 
that of current wheeze (table 4). However, ever having 
asthma showed a different pattern, with increases in 
high-income countries and Europe. For night cough, we 
found a consistent pattern of increase in point prevalence 
in both age groups, all country income groups, and most 
regions.
Discussion 
To our knowledge, GAN Phase I has provided the first 
standardised global estimates of trends over time in 
prevalence and severity of asthma symptoms in school-
aged children since 2003. The study included almost 
120 000 children from 27 centres in 14 countries using the 
same instruments and methods as ISAAC.9,10 We identified 
a substantial burden of asthma symptoms in school-aged 
children: in both age groups, about one in ten had wheeze 
in the preceding year, of whom almost half had severe 
symptoms. We modelled all ISAAC Phases I and III and 
GAN Phase I prevalence data over time to determine 
patterns of change over nearly three decades (1993–2020) 
and found prevalence and severity to vary by age group, 
country income, region, and centre.
Figure: Absolute changes over time in prevalence of current wheeze for adolescents (A) and children (B) by 
survey date
Each thin line represents one centre. The thick line shows the average absolute change from ISAAC Phase I to 
Phase III for those centres that did not participate in GAN Phase I. The span of the years of data collection for ISAAC 
Phase I, ISAAC Phase III, and GAN Phase I are shown. GAN=Global Asthma Network. ISAAC=International study of 
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We observed change in prevalence of all asthma 
symptoms by 2 SE or more in most centres, suggesting 
more than just random variation. In seven countries, we 
found a decrease in prevalence of most asthma symptoms, 
whereas increases were found in seven countries. There is 
evidence from the 27-year modelling of an overall decrease 
in prevalence for severe asthma symptoms in adolescents 
and an overall increased report of ever having asthma and 
night cough in both age groups. We also found regional 
differences, with evidence of increasing prevalence of 
current wheeze and severe asthma symptoms in Africa 
and Eastern Mediterranean and decreasing mean 
prevalence in South-East Asia and Western Pacific regions. 
Country income was associated with changes in prevalence 
of asthma symptoms, with low-income countries showing 
a significant decrease but lower-middle-income countries 
showing an increase, with no evidence of change in more 
affluent countries. These broad patterns overlie a 
substantial heterogeneity of trends both between and 
within countries. This limits the generalisability of 
conclusions from any single centre or country.
The interpretation of these patterns is complex because 
a wide range of risk factors exists and environmental 
changes are at play. Some centres had changes of 
particular interest. For example, large variations were 
found within India, and the reasons for this are subject 
to a national study. A few centres with high prevalence 
saw a progressive decrease from ISAAC Phases I to III7,8 
to GAN Phase I. Some low-prevalence centres showed 
increased prevalence of asthma symptoms, including 
severe asthma symptoms, contributing to the burden of 
asthma. A large increase in prevalence was found in 
Lattakia, in war-torn Syria. In two centres (Cape Town 
and Bilbao), the increase in prevalence of severe asthma 
symptoms was more than that of asthma symptoms; 
whether this is due to barriers to asthma care remains to 
Outcome Number of surveys* 
in strata
Current wheeze Severe asthma 
symptoms
Exercise wheeze Night cough Asthma ever
Model stratified by age group
Age 6–7 years –0·22 (–1·00 to 0·57) –0·24 (–0·63 to 0·15) 0·78 (–0·31 to 1·87) 3·21 (1·80 to 4·62) 0·56 (–0·13 to 1·24) 161
Age 13–14 years –0·43 (–1·10 to 0·23) –0·37 (–0·69 to –0·04) 0·34 (–0·58 to 1·26) 4·25 (3·06 to 5·44) 1·25 (0·67 to 1·83) 255
Model stratified by age group and income group
Age 6–7 years
Low income –1·37 (–2·47 to –0·27) –0·84 (–1·37 to –0·30) –0·02 (–1·54 to 1·50) 3·33 (1·34 to 5·32) –1·56 (–2·48 to –0·65) 31
Lower-middle income 1·99 (0·33 to 3·66) 1·32 (0·51 to 2·12) 3·66 (1·36 to 5·96) 5·29 (2·28 to 8·29) 0·06 (–1·33 to 1·44) 15
Upper-middle income 0·50 (–0·82 to 1·82) 0·20 (–0·44 to 0·84) 1·66 (–0·17 to 3·48) 1·41 (–0·98 to 3·80) 1·19 (0·09 to 2·28) 43
High income –0·22 (–1·24 to 0·80) –0·39 (–0·88 to 0·11) 0·25 (–1·16 to 1·66) 3·48 (1·63 to 5·32) 2·07 (1·22 to 2·92) 72
Age 13–14 years
Low income –1·67 (–2·70 to –0·64) –1·03 (–1·53 to –0·53) –0·58 (–2·00 to 0·85) 4·31 (2·45 to 6·17) –0·84 (–1·70 to 0·02) 47
Lower-middle income 1·69 (0·13 to 3·25) 1·13 (0·37 to 1·88) 3·10 (0·95 to 5·25) 6·26 (3·46 to 9·07) 0·78 (–0·52 to 2·08) 40
Upper-middle income 0·19 (–1·06 to 1·45) 0·01 (–0·60 to 0·62) 1·10 (–0·63 to 2·83) 2·38 (0·12 to 4·65) 1·91 (0·86 to 2·95) 62
High income –0·52 (–1·47 to 0·43) –0·58 (–1·04 to –0·12) –0·31 (–1·62 to 1·00) 4·45 (2·73 to 6·17) 2·79 (2·00 to 3·58) 106
Model stratified by age group and grouped region
Age 6–7 years
Africa and Eastern 
Mediterranean
2·61 (0·76 to 4·46) 1·46 (0·57 to 2·35) 4·99 (2·41 to 7·57) 6·64 (3·28 to 9·99) 0·21 (–1·38 to 1·79) 10
America 0·01 (–1·29 to 1·31) 0·13 (–0·50 to 0·76) 1·23 (–0·56 to 3·03) 1·43 (–0·92 to 3·77) 0·88 (–0·24 to 1·99) 29
Europe† 1·08 (–0·08 to 2·24) 0·43 (–0·13 to 0·99) 1·60 (–0·01 to 3·21) 4·67 (2·57 to 6·78) 2·73 (1·74 to 3·73) 64
South-East Asia and Western 
Pacific
–1·35 (–2·28 to –0·41) –0·96 (–1·41 to –0·51) –0·33 (–1·64 to 0·98) 2·71 (1·01 to 4·42) –0·69 (–1·49 to 0·11) 58
Age 13–14 years
Africa and Eastern 
Mediterranean
2·09 (0·40 to 3·78) 1·15 (0·33 to 1·96) 4·15 (1·80 to 6·51) 7·41 (4·34 to 10·47) 0·78 (–0·68 to 2·23) 34
America –0·51 (–1·73 to 0·71) –0·19 (–0·77 to 0·40) 0·39 (–1·29 to 2·07) 2·20 (0·00 to 4·40) 1·45 (0·40 to 2·50) 50
Europe† 0·56 (–0·51 to 1·63) 0·11 (–0·40 to 0·63) 0·76 (–0·73 to 2·25) 5·45 (3·50 to 7·39) 3·30 (2·38 to 4·22) 100
South-East Asia and Western 
Pacific
–1·87 (–2·78 to –0·96) –1·28 (–1·72 to –0·84) –1·17 (–2·44 to 0·10) 3·49 (1·83 to 5·14) –0·12 (–0·90 to 0·66) 71
Data are absolute percentage points difference (95% CI). Results from mixed model with random intercepts for country and centre, incorporating effect modification, fully adjusted for age group, income group, 
and grouped region (n=416). ISAAC=International Study of Asthma and Allergies in Childhood. *N=number of surveys contributing to each stratified analysis. †Malta was in ISAAC’s Eastern Mediterranean 
region but has been moved to the European region in modelling for this analysis.
Table 4: Model results of estimated change in all asthma related outcomes over 10 years
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be investigated. The influence of asthma programmes, 
accessibility of asthma medicines, or other environmental 
changes1 on these variations needs to be determined. 
National asthma programmes can be effective ways of 
reducing the burden of severe asthma symptoms: Costa 
Rica, India, and Taiwan reported national asthma 
strategies in 2013–14,22 which might be a factor in the 
decreased burden in Costa Rica and India, but not in 
Taiwan. The role of macro-environmental changes 
affecting populations is worthy of exploration.
The Global Burden of Disease (GBD) Study has reported 
estimates of global asthma prevalence (for all ages) over a 
similar period as this analysis. The GBD case definition for 
asthma differed from ours in that it was a reported 
diagnosis by a physician (which varies between countries) 
combined with wheezing in the preceding 12 months. The 
GBD estimates over 2000–17 showed large and unexplained 
variations between 220·4 and 339·4 million people.2,23–28 
Since 2003, no new worldwide standardised studies of 
asthma symptom prevalence were done until GAN 
Phase I, which also included additional 36 centres in 11 
countries that did not undertake ISAAC, not included in 
this Article, and should contribute to future GBD analyses.
Our study has many strengths, especially the 
standardised methods used to estimate asthma prevalence 
from symptoms in a wide range of settings in the world.6 
Tight quality control checks along with the same key 
personnel in ISAAC and GAN meant that replication of 
the standardised methods from ISAAC Phase I to Phase III 
to GAN Phase I was successful, as evidenced by the low 
number of centres excluded or with footnotes related to 
the methods. Response rates were high. The study includes 
many centres from low-income, middle-income, and high-
income countries from all regions of the world except 
North America. In about half of the centres, GAN Phase I 
was the first paired standardised study of asthma symptom 
prevalence; these included centres in five countries with 
no previous time-trend data (centres in Ecuador, Greece, 
Nicaragua, Sudan, and Syria), and nine centres that had no 
previous time-trend data (although different centres in 
those countries had provided ISAAC time-trend data).8
Our study has some limitations, which include the 
smaller number of GAN Phase I centres compared with 
that of ISAAC Phase I to Phase III, which makes it difficult 
to generalise the findings to global prevalence changes. 
Centres were self-selecting, and thus not representative of 
countries except for Costa Rica, which was a whole country 
study. Within an individual country, wide differences of 
prevalence can occur such as rural versus urban locations 
and high-income areas in a low-income or middle-income 
country. Despite the simplicity of the GAN and ISAAC 
approach, these surveys are more difficult to undertake 
now than at the time of ISAAC Phases I and III. Factors 
that increase this difficulty include reluctance of schools to 
being involved in research due to increased curriculum 
demands; more stringent ethical requirements, meaning 
that obtaining passive consent for adolescents is less easy 
than in previous decades;16 funders not prioritising 
population-based research; parents being busier and 
having less time for participation; and epidemics or 
pandemics (currently COVID-19) and conflicts that disrupt 
schools and people’s lives.
Future GAN Phase I reports will contribute an estimate 
of the global burden of asthma, which will include the 
GAN Phase I centres in this Article as well as centres 
without time-trend data, and analyses in children and 
adolescents assessing rhinocon junctivitis and eczema and 
other asthma risk factors, similar to ISAAC Phase III 
reports, as well as studies in adults. Extensive risk factor 
analyses were undertaken in ISAAC Phase III.29,30 
Equivalent analyses will be undertaken with use of GAN 
Phase I data in conjunction with ISAAC Phase III data to 
determine to what extent changes in risk factor prevalences 
over time can account for the observed changes in 
prevalence and severity of asthma symptoms. We will also 
examine the relationship of management of asthma and 
symptoms. Abundant evidence exists that in many 
locations in the world, asthma management is suboptimal, 
contributing to a relatively high prevalence of severe 
asthma symptoms,1,3 and there are strategies to improve 
this even in localities within low-resource settings.1,31 As 
the legacy of severe asthma in childhood can be chronic 
obstructive pulmonary disease in adults, reducing the 
burden of severe asthma symptoms in children is of 
crucial importance.2
These data suggest that, while the overall worldwide 
prevalence of asthma symptoms is relatively stable, about 
one in 20 school-aged children have severe asthma 
symptoms, and they need to gain better asthma control 
to lessen the associated avoidable asthma morbidity and 
mortality; little has changed over 27 years. The UN 
2030 Sustainable Development Goal 3 aims to “ensure 
healthy lives and promote wellbeing at all ages”.1 Our 
findings emphasise the urgency of ensuring that the 
high worldwide burden of severe asthma symptoms in 
children is mitigated by enabling equitable and affordable 
access to the effective therapies for asthma that have 
been available to those who can afford them for decades.
The Global Asthma Network Phase I Study Group
GAN Steering Group: M I Asher, K Bissell, C-Y Chiang, A El Sony, 
E Ellwood, P Ellwood, L García-Marcos, G B Marks, R Masekela, 
E Morales, K Mortimer, N Pearce, D P Strachan. 
GAN International Data Centres: GAN Global Centre M I Asher, 
P Ellwood, E Ellwood; Murcia, Spain L García-Marcos, 
V Pérez-Fernández, E Morales, A Martinez-Torres; London, UK 
D P Strachan, N Pearce, C E Rutter, S Robertson, R J Silverwood. 
GAN Principal Investigators: Chile J Mallol; Costa Rica M Soto-Martinez; 
Ecuador A Cabrera Aguilar; Greece K Douros; India M Sabir, M Singh, 
V Singh*, T U Sukumaran, S Awasthi, S K Kabra, S Salvi; Mexico 
R García-Almaráz, J V Mérida-Palacio, B E Del Río Navarro*, 
S N González-Díaz, E M Navarrete-Rodriguez; New Zealand M I Asher; 
Nicaragua J F Sánchez; Nigeria A G Falade; South Africa H J Zar; Spain 
A López-Silvarrey Varela, C González Díaz, L García-Marcos*; Sudan 
M Nour; Syria G Dib, Y Mohammad*; Taiwan J-L Huang; Thailand 
S Chinratanapisit. 
Other GAN National Coordinators: Costa Rica M E Soto-Quiros; Sudan 
A El Sony; Thailand P Vichyanond. 
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M Baeza-Bacab; Sudan A El Sony; Syria S Mohammad.
ISAAC Phase I Principal Investigators: Chile E Cortéz; Costa Rica 
M E Soto-Quirós*; Greece C H Gratziou*; India L Kumar†, 
T U Sukumaran, K Chopra, N M Hanumante; New Zealand M I Asher*; 
Nigeria B O Onadeko; South Africa H Nelson; Spain A D Rubio, 
L García-Marcos*; Taiwan K Hsieh†; Thailand P Vichyanond*. 
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